CBIO - Catalyst Biosciences, Inc.
| Previous Close | 6.52 |
| Open | 6.58 |
| Bid | 6.58 x 800 |
| Ask | 6.59 x 800 |
| Day's Range | 6.54 - 6.69 |
| 52 Week Range | 4.52 - 10.84 |
| Volume | 90,725 |
| Avg. Volume | 601,547 |
| Market Cap | 80.433M |
| Beta (5Y Monthly) | 2.32 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -4.37 |
| Earnings Date | Nov. 06, 2019 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | Aug. 19, 2015 |
| 1y Target Est | 24.75 |
- GlobeNewswire
Catalyst Biosciences Announces Closing of Public Offering of Common Stock
Catalyst Biosciences, Inc. (CBIO), a clinical-stage biopharmaceutical company developing novel treatments for hemophilia and other rare bleeding disorders, (the Company), today announced the closing of an underwritten public offering of 5,307,692 shares of its common stock, offered at a price of $6.50 per share to the public, which includes the exercise in full by the underwriters of their 30-day option to purchase up to an additional 692,307 shares of its common stock. The gross proceeds to the Company from this offering were approximately $34.5 million, before deducting underwriting discounts and commissions and other estimated offering expenses payable by the Company.
- GlobeNewswire
Catalyst Biosciences Announces Pricing of Public Offering of Common Stock
Catalyst Biosciences, Inc. (CBIO), a clinical-stage biopharmaceutical company developing novel treatments for hemophilia and other rare bleeding disorders, (the Company), today announced the pricing of an underwritten public offering of 4,615,385 shares of its common stock, offered at a price of $6.50 per share to the public. Additionally, the Company has granted the underwriters a 30-day option to purchase up to an additional 692,307 shares of its common stock. All of the shares in the offering are being offered by the Company.
- GlobeNewswire
Catalyst Biosciences Announces Proposed Public Offering of Common Stock
Catalyst Biosciences, Inc. (CBIO), a clinical-stage biopharmaceutical company developing novel treatments for hemophilia and other rare bleeding disorders (the Company), today announced that it is offering shares of its common stock in an underwritten public offering. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. In addition, the Company expects to grant the underwriters of the offering a 30-day option to purchase up to an additional 15% of the number of shares of common stock offered in the public offering.
- GlobeNewswire
Catalyst Biosciences Presents Positive Data from its Phase 2b Trial of Subcutaneous Dalcinonacog Alfa (DalcA) and Marzeptacog alfa (activated) (MarzAA) Programs at the 13th Annual EAHAD Congress
Catalyst Biosciences, Inc. (CBIO), today announced positive efficacy and safety data from its Phase 2b trial of DalcA, a next-generation subcutaneously (SQ) administered Factor IX (FIX) therapy being developed for the treatment of hemophilia B. The data were presented by Johnny Mahlangu, M.B.B.Ch., M.Med, F.C.Path, professor of haematology, faculty of health sciences, head of the School of Pathology at the University of Witwatersrand in Johannesburg, South Africa, and principal investigator in the clinical trial in an oral presentation at the 13th Annual Congress of the European Association for Haemophilia and Allied Disorders (EAHAD) in The Hague, Netherlands. Data from the trial showed that 28 days of daily SQ dosing of DalcA achieved protective target FIX levels of 12%, with steady state FIX levels of up to 27% after 14 days with no bleeds, demonstrating effective prophylaxis and the potential for lower or less frequent dosing.
- GlobeNewswire
Catalyst Biosciences Announces Oral and Poster Presentations at the 13th Annual EAHAD Congress
SOUTH SAN FRANCISCO, Calif., Jan. 27, 2020 -- Catalyst Biosciences, Inc. (NASDAQ: CBIO), today announced one oral and three poster presentations at the 13th Annual Congress of.
- GlobeNewswire
Catalyst Biosciences Announces Addition of Geoffrey Shiu Fei Ling, M.D. and Sharon Tetlow to Board of Directors
Catalyst Biosciences, Inc. (CBIO), a clinical-stage biopharmaceutical company developing novel treatments for hemophilia and other rare bleeding disorders, today announced the appointment of Geoffrey Shiu Fei Ling, M.D. and Sharon Tetlow to the Company’s Board of Directors, effective January 15, 2020. Ms. Tetlow is Managing Partner and Founder of Potrero Hill Advisors. Throughout her career as a serial Chief Financial Officer, Ms. Tetlow has held board seats, served on Audit and Transaction Committees through successful acquisitions, served as the board’s financial expert and has been the CFO of public companies.
- Simply Wall St.
Imagine Owning Catalyst Biosciences (NASDAQ:CBIO) And Wondering If The 31% Share Price Slide Is Justified
It is a pleasure to report that the Catalyst Biosciences, Inc. (NASDAQ:CBIO) is up 38% in the last quarter. But that...
- GlobeNewswire
Catalyst Biosciences Announces Global License and Collaboration Agreement to Develop Pegylated CB 2782 for the Treatment of Dry Age-Related Macular Degeneration
Catalyst Biosciences, Inc. (CBIO), today announced it has entered into a global license and collaboration agreement with Biogen Inc. (BIIB) for the development and commercialization of pegylated CB 2782 (CB 2782-PEG) for the potential treatment of geographic atrophy (GA) associated dry age-related macular degeneration (dry AMD). Under the terms of the agreement, Biogen will receive an exclusive worldwide license to develop and commercialize CB 2782-PEG and Catalyst’s other anti-C3 proteases for the potential treatment of dry AMD. Catalyst will perform pre-clinical and manufacturing activities and Biogen will be solely responsible for funding the pre-clinical and manufacturing activities and performing Investigational New Drug (IND)-enabling activities, worldwide clinical development, and commercialization.
- GlobeNewswire
Catalyst Biosciences Presents Two Posters on MarzAA at the 61st Annual American Society of Hematology Conference
Catalyst Biosciences, Inc. (CBIO), a clinical-stage biopharmaceutical company developing novel treatments for hemophilia and other rare bleeding disorders, today announced two poster presentations on Marzeptacog alfa (activated) – MarzAA, the Company’s subcutaneously administered next-generation engineered coagulation Factor VIIa (FVIIa), at the 61st Annual American Society of Hematology (ASH) meeting held December 7-10, 2019 in Orlando, Florida. In the first poster, entitled: Fast Onset of Action of Subcutaneously Administered Marzeptacog Alfa (Activated) Supports On-Demand Treatment in Hemophilia A Mice, Dr. Grant Blouse, PhD, vice president of translational research at Catalyst Biosciences presented data demonstrating MarzAA’s potential as an on-demand therapy to treat acute ongoing bleeding in hemophilia.
- GlobeNewswire
Catalyst Biosciences to Present at the Stifel Healthcare Conference
Catalyst Biosciences, Inc. (CBIO), today announced that Nassim Usman, Ph.D., president and chief executive officer of Catalyst Biosciences, will present a corporate overview at the Stifel 2019 Healthcare Conference at 9:10 a.m. ET on Tuesday, November 19, 2019, in New York.
- GlobeNewswire
Catalyst Biosciences Reports Third Quarter 2019 Operating & Financial Results and Provides a Corporate Update
SOUTH SAN FRANCISCO, Calif., Nov. 07, 2019 -- Catalyst Biosciences, Inc. (NASDAQ: CBIO) today announced its operating and financial results for the third quarter ended.
- GlobeNewswire
Catalyst Biosciences Announces Poster Presentations at the 61st Annual American Society of Hematology Conference
SOUTH SAN FRANCISCO, Calif., Nov. 06, 2019 -- Catalyst Biosciences, Inc. (NASDAQ: CBIO), a clinical-stage biopharmaceutical company developing novel medicines to address.
- Simply Wall St.
We're Keeping An Eye On Catalyst Biosciences's (NASDAQ:CBIO) Cash Burn Rate
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...
- GlobeNewswire
Catalyst Biosciences Provides DalcA Phase 2b Trial Update
Catalyst Biosciences, Inc. (CBIO), today provided an update on enrollment in its Phase 2b study of dalcinonacog alfa (DalcA), a next-generation subcutaneously (SQ) administered Factor IX (FIX) therapy being developed for the treatment of hemophilia B. Two subjects have completed dosing and washout, Factor IX levels in these two subjects exceeded the trial efficacy endpoint of 12% activity and no anti-drug antibodies were detected. Enrollment is ongoing and the Company anticipates reporting final data in the first half of 2020. “We believe that DalcA may offer a conveniently-dosed subcutaneous prophylactic treatment option that could significantly improve the quality of life for those suffering from severe hemophilia B,” said Nassim Usman, Ph.D., president and chief executive officer of Catalyst.
- Zacks
Catalyst Biosciences Enters Oversold Territory
Catalyst Biosciences, Inc. (CBIO) has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock.
- GlobeNewswire
Catalyst Biosciences to Present at the Cantor Global Healthcare Conference
Catalyst Biosciences, Inc. (CBIO), today announced that Nassim Usman, Ph.D., president and chief executive officer of Catalyst Biosciences, will present a corporate overview at the Cantor 2019 Global Healthcare Conference at 8:20 a.m. ET on Thursday, October 3, 2019, in New York. Catalyst is a clinical-stage biopharmaceutical company developing novel medicines to address hematology indications. Catalyst has engineered a portfolio of compounds that have increased potency over the naturally occurring proteases.
- Simply Wall St.
Are Insiders Selling Catalyst Biosciences, Inc. (NASDAQ:CBIO) Stock?
We've lost count of how many times insiders have accumulated shares in a company that goes on to improve markedly. The...
- GlobeNewswire
Catalyst Biosciences Announces Transition of Chief Financial Officer
Catalyst Biosciences, Inc. (CBIO), today announced that its chief financial officer, Fletcher Payne, will be stepping down from the Company to pursue another opportunity effective August 30, 2019. The Company is initiating a search for a successor. “Fletcher has been a valuable member of our management team and I thank him for his contributions over the past four years,” said Nassim Usman, Ph.D., chief executive officer of Catalyst.
- Simply Wall St.
How Should Investors Feel About Catalyst Biosciences, Inc.'s (NASDAQ:CBIO) CEO Pay?
Nassim Usman became the CEO of Catalyst Biosciences, Inc. (NASDAQ:CBIO) in 2015. First, this article will compare CEO...
- GlobeNewswire
Catalyst Biosciences to Present at the 2019 Hemophilia Drug Development Summit
SOUTH SAN FRANCISCO, Calif., Aug. 16, 2019 -- Catalyst Biosciences, Inc. (NASDAQ: CBIO), today announced an oral presentation at the Second Annual 2019 Hemophilia Drug.
- GlobeNewswire
Catalyst Biosciences to Host Key Opinion Leader Meeting on Next-Generation Subcutaneous Factor VIIa Marzeptacog Alfa (Activated) in Patients with Bleeding Disorders on August 15
Catalyst Biosciences, Inc. (CBIO), today announced that it will host a Key Opinion Leader (KOL) meeting on next-generation subcutaneous Factor VIIa (FVIIa) marzeptacog alfa (activated) (MarzAA) in individuals with bleeding disorders on Thursday, August 15 in New York City. The event will feature presentations by KOLs Robert Klamroth, M.D., Ph.D., Vivantes Hospital, Berlin, Germany, and Steven W. Pipe, M.D., C. S. Mott Children's Hospital, Ann Arbor, MI.
- GlobeNewswire
Catalyst Biosciences Reports Second Quarter 2019 Operating & Financial Results and Provides a Corporate Update
Phase 2 trial of subcutaneously administered MarzAA met primary endpoint of reduction in annualized bleed rate demonstrating safety and clinical efficacy, with 90% reduction.
- Simply Wall St.
If You Had Bought Catalyst Biosciences (NASDAQ:CBIO) Stock Three Years Ago, You'd Be Sitting On A 68% Loss, Today
If you are building a properly diversified stock portfolio, the chances are some of your picks will perform badly. But...
